Gastrointestinal

Colorectal:

CIRB #H-37277/ CTSU #A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

CIRB #pend/ CTSU #A021703 (SOLARIS): Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS) (not yet submitted to IRB)

Neuroendocrine:

CIRB #H-38045 / CTSU #A021602 (CABINET):  Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus

HIRB #H-38781/ TARVEDA #PEN-221:  A Phase 1/2a, open label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advanced cancers, including gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of lung

Anal:

CIRB #H-38309/ CTSU #EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Liver/Bile Ducts:

HIRB #2019-51/ Merck #KEYNOTE-937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)

HIRB #2019-56/ Incyte #INCB-302 (FIGHT-302): A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement

HIRB #H-38983/ Lexicon #1606-207 (TELE-ABC): A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC) (pending IRB approval)

GI Cancers:

IRB #H-38168/ DFCI El Centro: Engaging Latinos in the Center of Cancer Treatment options – RCT of Usual Chemotherapy Educational Tools Versus Investigational Chemotherapy Educational Tools